Stock Comparison

BEAM vs LLY

Beam Therapeutics Inc vs Eli Lilly and Co

The Verdict

BEAM takes this one.

Winner

BEAM

Beam Therapeutics Inc

9.4

out of 10

Hidden Gem

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$3.2B

Market Cap

$965.0B

-5.2

P/E Ratio

52.6

-39.7%

Profit Margin

N/A

-5.9%

Return on Equity

N/A

0.2

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

9.4

DVR Score

0.5

The Deep Dive

BEAM9.4/10

Beam Therapeutics retains exceptionally high 10x growth potential, driven by its proprietary base editing platform, which continues to promise precision genetic cures. The recent Q1 2026 earnings report (May 7, 2026) provided critical clarity, showing a robust cash position of $1.2B against only $100M in debt, significantly de-risking financial runway concerns. Revenue surged +323% YoY, and EPS im...

Full BEAM Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.